Literature DB >> 8452259

Prolonged administration of isoflurane to pediatric patients during mechanical ventilation.

J H Arnold1, R D Truog, S A Rice.   

Abstract

We undertook a prospective study of the effectiveness and potential toxicities of isoflurane sedation in pediatric patients undergoing mechanical ventilation who required large doses of opioids for sedation were considered eligible. Ten patients (ages 3 wk to 19 yr) received continuous isoflurane sedation for a mean duration of 131 minimum alveolar concentration (MAC)-hours (range 13-497 MAC-hours). The mean peak inorganic fluoride (F-) concentration was 11.0 microM, and the highest F- concentration was 26.1 microM after 441 MAC-hours. Only one patient had a measured F- concentration greater than 20 microM. No abnormalities were noted in serum creatinine or osmolality. Creatinine clearances were available for five patients who received a mean of 193 MAC-hours of isoflurane (range 33-497 MAC-hours), and only one patient had a persistent decrease from baseline of more than 20%. Five patients demonstrated an abstinence syndrome which consisted of nonpurposeful movements and extreme agitation. All of these patients had received at least 70 MAC-hours of isoflurane. Our experience indicates that isoflurane can effectively provide sedation to pediatric patients for prolonged periods without significant adverse effects on cardiovascular, hepatic, or renal function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452259     DOI: 10.1213/00000539-199303000-00011

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  13 in total

Review 1.  Sedation and analgesia in paediatric intensive care units: a guide to drug selection and use.

Authors:  J D Tobias
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Dexmedetomidine: Are There Going to be Issues with Prolonged Administration?

Authors:  Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

3.  [AnaConDa].

Authors:  C Sirtl; H Laubenthal; A Meiser
Journal:  Anaesthesist       Date:  2007-12       Impact factor: 1.041

4.  [Sedation concepts with volatile anaesthetics in intensive care: practical use and current experiences with the AnaConDa system].

Authors:  J Kompardt; K Schärff; K Kubosch; C Pohl; M Bomplitz; J Soukup
Journal:  Anaesthesist       Date:  2008-12       Impact factor: 1.041

5.  Targeted Versus Continuous Delivery of Volatile Anesthetics During Cholinergic Bronchoconstriction.

Authors:  Jarred R Mondoñedo; John S McNeil; Jacob Herrmann; Brett A Simon; David W Kaczka
Journal:  J Eng Sci Med Diagn Ther       Date:  2018-05-09

6.  Isoflurane decreases proliferation and differentiation, but none of the effects persist in human embryonic stem cell-derived neural progenitor cells.

Authors:  Hye-Min Sohn; Hye Young Kim; Seongjoo Park; Sung-Hee Han; Jin-Hee Kim
Journal:  J Anesth       Date:  2016-11-05       Impact factor: 2.078

7.  Isoflurane for life-threatening bronchospasm: a 15-year single-center experience.

Authors:  David A Turner; David Heitz; Mehrengise K Cooper; P Brian Smith; John H Arnold; Scot T Bateman
Journal:  Respir Care       Date:  2012-03-13       Impact factor: 2.258

8.  Volatile Anesthetics and the Treatment of Severe Bronchospasm: A Concept of Targeted Delivery.

Authors:  Jarred R Mondoñedo; John S McNeil; Samir D Amin; Jacob Herrmann; Brett A Simon; David W Kaczka
Journal:  Drug Discov Today Dis Models       Date:  2014-04-29

9.  Outpatient therapy of iatrogenic drug dependency following prolonged sedation in the pediatric intensive care unit.

Authors:  J D Tobias; J K Deshpande; D F Gregory
Journal:  Intensive Care Med       Date:  1994-08       Impact factor: 17.440

Review 10.  [Neurotoxicity of general anesthetics in childhood: does anesthesia leave its mark on premature babies, newborns and infants?].

Authors:  B Sinner; K Becke; K Engelhard
Journal:  Anaesthesist       Date:  2013-02       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.